Stem cells have been used since the 1910 for its healing benefits and currently have its widest application in ophthalmology, corneal regeneration repair.
Stem cells for the treatment of chronic pelvic pain conditions is derived from amniotic fluid which is rich in growth factors, carbohydrates, lipids, enzymes, exosomes, micro RNAs and hormones. The combination of all these constituents help in tissue regeneration with the exosomal microRNAs doing the bulk of the actual regenerative activity. These components work at the site of injury where the patient's own stem cell in the in the tissue differentiate into new cells and the injured tissue regenerate, repair and restore back to its normal state.
Amniotic fluid therefore has anti-inflammatory, immunomodulatory properties and promotes epithelial healing, reduces inflammation, suppresses pain, fibrosis, bacterial growth and decreases the severity of insufficient vascularization in any setting.
Amniotic tissue and fluid are regulated by the Food and Drug Administration (FDA) under Section 361 of the Public Health Service Act (PHSA), Code for Federal Regulation (CFR) 1271.3 and 1271.10, as a minimally manipulated tissue allograft.
Stem cells are currently being used in the treatment of Pudendal neuralgia and chronic interstitial cystitis and are approved by major insurances including Medicare.
